Velsera
Velsera is a global precision medicine technology company that provides AI-enhanced software platforms — including the Seven Bridges Platform, Clinical Genomics Workspace, and an IVD-grade Knowledgebase — and professional services to biotech and pharma companies, clinical diagnostic laboratories, NGS assay manufacturers, and non-profit research organizations.
- Company typePrivate
- Founded2023
- HeadquartersCharlestown, United States
- Headcount251–500
- GTM typeB2B
- OfferingSoftware
What Velsera does
Velsera is a global precision medicine technology company founded in 2023 by Summa Equity through the merger of Seven Bridges, PierianDx, and UgenTec. The company provides integrated AI-enhanced software and services that accelerate the discovery, development, and delivery of precision medicine, operating from its Boston headquarters with presence in the US, Europe, and Asia. Its core technology stack includes the Seven Bridges Platform (a Trusted Research Environment for bioinformatic analysis), the Clinical Genomics Workspace/CGW Plus (flagship tertiary analysis and reporting platform for NGS testing), an IVD-grade Knowledgebase powering variant interpretation (including Illumina's FDA-approved TruSight Oncology Comprehensive test), GRAF (an award-winning graph-based pangenome reference tool), ARIA (data harmonization and secure sharing), and RHEO (workflow automation for bioinformatics). The Global Data Network, launched in 2025, provides federated access to 175+ million patient records across 50+ global data providers for pharma and biotech R&D.
Velsera serves four primary customer segments: biotech and pharma (supporting 7 of the top 10 global pharmaceutical companies), clinical diagnostic laboratories (80+ active NGS lab customers processing 250,000+ samples annually), NGS assay and equipment manufacturers, and non-profits/government agencies. The company addresses concrete pain points including variant interpretation bottlenecks, FDA LDT compliance, multi-modal data silos, and slow discovery-to-diagnostic timelines. Its professional services arm deploys 150+ scientists, bioinformaticians, and engineers to support regulatory navigation, bioinformatics workflow design, and clinical lab scaling.
The business model combines SaaS platform subscriptions (Seven Bridges Platform, CGW, Knowledgebase, GRAF, ARIA) with project-based professional services, distributed through a sales-led enterprise GTM motion with quote-based annual agreements. Channel partnerships (Diagnostica Longwood for Iberia, Genoks for Turkey) extend reach into regional markets. Revenue is not publicly disclosed, but operational scale metrics — 18,000+ researchers on Seven Bridges, 250,000+ annual NGS samples, 50+ data partners, and +20% YoY sequencing volume growth — indicate a substantial enterprise footprint. Recent strategic moves include the launch of the Global Data Network, OEM partnership with Illumina on TSO Comprehensive, and senior leadership appointments in 2026 (Jamie Coffin as CEO, Kareem Saad as President and CBO) suggesting a commercial scaling phase.
Velsera firmographics
Firmographics- Name
- Velsera
- Legal name
- Velsera Inc.
- Website
- https://velsera.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Velsera is a global precision medicine technology company that provides AI-enhanced software platforms — including the Seven Bridges Platform, Clinical Genomics Workspace, and an IVD-grade Knowledgebase — and professional services to biotech and pharma companies, clinical diagnostic laboratories, NGS assay manufacturers, and non-profit research organizations.
- Ownership category
- akta.pro rank
Velsera industry classification
Industry- Product category
- Clinical Genomics Software & Bioinformatics Platforms
- NAICS
- Software Publishers (513210), Custom Computer Programming Services (541511), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Prepackaged Software (7372), Services-Computer Programming, Data Processing, Etc. (7370), Services-Computer Programming Services (7371), Services-Health Services (8000)
- akta.pro primary industry
- Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF)
- akta.pro secondary industries
- Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Record Locator Services (RLS) & Longitudinal Record Aggregation (HLACABAH)
Keywords
Where Velsera is headquartered
LocationHeadquarters
- HQ city
- Charlestown
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Velsera business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Software Platform Subscriptions: SaaS-based software platform licensing for the Seven Bridges Platform, Clinical Genomics Workspace, and related analytics tools. Platforms support research, translational research, and clinical genomics workflows with enterprise agreements, data processing addendums, and statements of work governing protected health information processing.
- Professional Services: In-house expert services including data harmonization, bioinformatics, scientific support, regulatory compliance (FDA LDT guidance, IVD verification), and clinical services supporting labs to start and scale NGS testing. Services include over 150 scientists, bioinformaticians, and engineers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise agreements with tailored pricing based on organizational requirements, sequencing volumes, and service scope. |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels9 records
Velsera product offering
Product offeringCore offering
Velsera is a global precision medicine technology company that sells integrated AI-enhanced software platforms and professional services for clinical genomics, multi-omic data analysis, and bioinformatics. Its core offerings include the Seven Bridges Trusted Research Environment, Clinical Genomics Workspace (CGW), Knowledgebase for variant interpretation, GRAF reference genome tool, ARIA data harmonization platform, RHEO workflow automation, and the Global Data Network providing federated access to 175M+ patient records. These are sold primarily through enterprise SaaS subscriptions and professional services engagements to biotech/pharma, clinical diagnostic labs, and public-sector genomics programs.
Product overview
Velsera is a global precision medicine technology company offering an integrated platform-plus-modules architecture combining AI-enhanced software and services. The core technology suite includes the Seven Bridges Platform (Trusted Research Environment for bioinformatic analysis), Clinical Genomics Workspace/CGW Plus (flagship tertiary analysis and reporting for NGS testing), Knowledgebase (IVD-grade variant interpretation knowledge base), GRAF (graph-based reference genome tool), and ARIA (data harmonization and secure sharing). RHEO provides workflow automation embedded in the Seven Bridges Platform. The Global Data Network provides federated access to 175+ million patient records. Solutions span clinical & multi-omic data access, analysis & bioinformatics, companion diagnostic development, NGS assay development, IVD compliance transition, and clinical interpretation & reporting. The company operates across the US, Europe, and Asia, serving biotech/pharma, clinical diagnostic labs, NGS assay manufacturers, and non-profits/government agencies.
Differentiator
Problem solved
Functional benefit
Brands
- Seven Bridges Platform: Trusted Research Environment (TRE) for bioinformatic analysis and pipeline development. Includes RHEO automation capabilities.
- GRAF
- ARIA
- Clinical Genomics Workspace (CGW)
- Knowledgebase
- Global Data Network (GDN)
- FastFinder
Products and services
- Seven Bridges Platform Trusted Research Environment (TRE) for bioinformatic analysis and pipeline development, enabling researchers to execute complex genomic analyses and access petabytes of public and private data; supports 18,000+ researchers.
- Clinical Genomics Workspace (CGW) Flagship tertiary analysis and reporting platform delivering confident decision support for NGS testing in clinical diagnostics, providing variant quality assessment and adaptive learning.
- CGW Plus Enhanced version of CGW featuring variant quality assessment, clinical evidence review, and adaptive learning and memory capabilities for oncology biomarker interpretation.
- Knowledgebase Best-in-class, IVD-grade variant interpretation knowledge base powering clinical decision support, including the knowledge behind Illumina's TruSight Oncology Comprehensive Test.
- GRAF (Genome Reference Annotation Flow) Award-winning reference genome tool using graph-based approaches to capture full value of diverse genomes, including African and Native American ancestries.
- ARIA Data harmonization and secure sharing platform enabling integration and sharing of multi-modal data across organizations.
- RHEO Automation framework built into the Seven Bridges Platform for executing complex, high-volume bioinformatics analyses without advanced computational skills.
- Global Data Network (GDN) Federated data ecosystem spanning 175+ million patient records across 50+ global data providers, bridging EMR, genomics, proteomics, transcriptomics, pathology, and radiology for pharma R&D.
- Professional Services: Data Harmonization In-house expert services supporting health and life science companies to combine and harmonize their data, delivered by 150+ scientists, bioinformaticians, and engineers.
- Professional Services: Bioinformatics In-house expert bioinformatics services supporting researchers and diagnostic developers to build better workflows.
- Professional Services: Regulatory
Quantifiable outcome
- 7/10 top pharmaceutical companies supported by Velsera technology-enabled products and services
- +8 more outcomes
Companies that use Velsera
Customer profileNamed customers19 records
Segments4 records
Ideal customer profiles4 records
Velsera technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability5 records
Feature7 records
Velsera partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- IlluminacoreVelsera powers the Knowledgebase behind Illumina's TruSight Oncology Comprehensive Test, now approved in Japan. This IVD-grade variant interpretation knowledge base supports comprehensive genomic profiling for cancer diagnostics.
- Diagnostica LongwoodcorePartnership to revolutionize access to precision genomics for patients in Spain and Portugal, with Diagnostica Longwood distributing and supporting Velsera's technologies in the Iberian Peninsula.
- Genoks GDHMcoreStrategic partnership to advance cancer diagnostics in Turkey, enabling local access to precision genomics technologies and supporting the expansion of NGS testing capabilities in the region.
- SentieonminorJoint development of Pangenotyper solution using graph-based pangenome reference for enhanced variant calling, which won Bio-IT World 2024 Best-of-Show award.
- Solaris HealthcorePartnership to expand access to genetic testing for urology patients to help understand cancer risks, enabling broader patient access to precision medicine diagnostics.
- Arima GenomicsminorPartnership to enable broad adoption of Arima Gene Fusion Test in clinical laboratories, integrating Arima's testing technology with Velsera's clinical genomics workflow platform.
Scale indicators11 records
Recent moves7 records
Expansion highlights6 records
Velsera competitors and assessment
Company assessmentDirect peers
- DNAnexus: DNAnexus provides a cloud-based biomedical informatics and data management platform for genomic and clinical data. Like Velsera's Seven Bridges Trusted Research Environment, it hosts large-scale NGS pipelines for pharma and clinical labs, making it the closest direct competitor on the research informatics side.
- Congenica: Congenica provides a clinical genomics interpretation platform used in rare disease and oncology diagnostics. It overlaps directly with Velsera's Clinical Genomics Workspace and Knowledgebase in clinical NGS interpretation workflows for hospital and reference labs.
- BC Platforms: BC Platforms operates a genomic data platform with a BCRQUEST.com data network of real-world clinical and genomic records, comparable to Velsera's Global Data Network. It serves pharma R&D and clinical diagnostics with a similar data-access and analytics model.
- SOPHiA Genetics: SOPHiA Genetics offers an AI-driven platform for genomic analysis and interpretation used by clinical labs and hospitals worldwide. It competes head-to-head with Velsera's CGW/CGW Plus for tertiary NGS analysis and variant interpretation, particularly in oncology and rare disease applications.
- Fabric Genomics (Genomic Health / Exact Sciences): Fabric Genomics (acquired by Genomic Health / Exact Sciences) provides AI-based NGS interpretation software for hereditary and oncology testing. Its interpretation capabilities compete with CGW in clinical labs scaling NGS testing for germline and somatic variants.
Broad incumbents
- Illumina (DRAGEN / Connected Software): Illumina is the dominant sequencing platform vendor and now offers DRAGEN secondary analysis and Connected Software tertiary pipelines. It is both a partner (via the TSO Comprehensive / Knowledgebase relationship) and a competitive threat vertically integrating into clinical interpretation workflows where CGW operates.
- Flatiron Health: Flatiron Health (a Roche subsidiary) operates a real-world oncology data platform that aggregates de-identified clinical and molecular data from cancer clinics. It is a broad incumbent comparable to Velsera's Global Data Network in pharma R&D data access for oncology.
- Roche (navify / Foundation Medicine): Roche operates the navify digital diagnostics platform and Foundation Medicine for companion diagnostics and oncology data. As a leading IVD and pharma company vertically integrating into clinical genomics informatics, it represents a broad incumbent comparable to Velsera's companion diagnostic and clinical interpretation stack.
Emerging players
- Lifebit: Lifebit provides federated genomics and biomedical data platforms (e.g., Lifebit CloudOS) for national genomics initiatives and pharma. It is an emerging peer with partial overlap to Seven Bridges on Trusted Research Environments and federated genomic data analysis.
- Seqera Labs: Seqera (the commercial entity behind Nextflow) provides cloud-native scientific workflow orchestration for bioinformatics pipelines. It competes with portions of Velsera's Seven Bridges / RHEO pipeline automation stack in life sciences research workflows.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat7 records
Key risks5 records
Key highlights6 records
Customer concentration
Velsera social profiles
Digital presenceVelsera compliance and trust
Trust signalCompliance4 records
Velsera financial estimates
Financial estimateRevenue estimate
Valuation estimate
Velsera leadership team
Management profileNumber of profiles
Profiles9 records
Velsera subsidiaries and ownership
Company hierarchySubsidiaries3 records
Velsera funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Velsera M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Velsera
What does Velsera do?
Velsera is a global precision medicine technology company that sells integrated AI-enhanced software platforms and professional services for clinical genomics, multi-omic data analysis, and bioinformatics. Its core offerings include the Seven Bridges Trusted Research Environment, Clinical Genomics Workspace (CGW), Knowledgebase for variant interpretation, GRAF reference genome tool, ARIA data harmonization platform, RHEO workflow automation, and the Global Data Network providing federated access to 175M+ patient records. These are sold primarily through enterprise SaaS subscriptions and professional services engagements to biotech/pharma, clinical diagnostic labs, and public-sector genomics programs.
Is Velsera a public or private company?
Velsera is a private company. It is classified as private equity controlled and is currently operating.
When was Velsera founded?
Velsera was founded in 2023. It employs 251 to 500 people.
Where is Velsera based?
Velsera is headquartered in Charlestown, United States, in the North America region.
How does Velsera make money?
Two revenue lines are on record. Software Platform Subscriptions are the primary driver. The others are professional Services.
Who are Velsera's main competitors?
Direct peers on record are DNAnexus, Congenica, BC Platforms, SOPHiA Genetics and Fabric Genomics (Genomic Health / Exact Sciences). Broad incumbents are Illumina (DRAGEN / Connected Software), Flatiron Health and Roche (navify / Foundation Medicine). Emerging players are Lifebit and Seqera Labs.
Does Velsera have an API?
No public API is recorded for Velsera.
What industry is Velsera in?
Velsera's product category is Clinical Genomics Software & Bioinformatics Platforms. Its primary akta.pro industry code is HLAGAJAF, Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D), with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 513210 and its SIC code is 7372.